Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Singulex, a provider of diagnostic technologies, has closed a $19 million financing round, led by Jafco and supported by existing investors including OrbiMed Advisors and Fisk Ventures.
Subscribe to our email newsletter
The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for Jafco Life Science Investment, will join the company’s board of directors.
Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I, a well-validated marker for cardiac necrosis, said Singulex.
Philippe Goix, CEO of Singulex, said: “With these funds, we are confident we have the resources to develop our immunoassay technology for use in the diagnostics field. Already, the assays we have developed and optimized for our pharmaceutical partners have enabled them to see biomarker level differences in blood samples with and without drugs that they had not been able to see before, thus offering new insights for their clinical trials.”